Programa Franco-argentino de Estudio del Cáncer de Páncreas, Buenos Aires, Argentina; Gastroenterology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Auto-generated profile, based on publicly available information
Analia Verónica Pasqua
Programa Franco-argentino de Estudio del Cáncer de Páncreas, Buenos Aires, Argentina; Gastroenterology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
This international, multidisciplinary consensus report represents the first effort to systematically define and characterize fatty pancreas. A key outcome of this endeavor was the recommendation to adopt “fatty pancreas” as the standardized and inclusive term to describe all forms of fat accumulation in the pancreas. This terminological consensus provides a critical foundation for unified reporting and clinical communication. Another major contribution of the report is the consensus on diagnostic imaging findings, which was based on radiological and endoscopic modalities. The proposed criteria aim to enhance consistency in clinical assessment and support the development of standardized research protocols. In addition to establishing terminology and diagnostic frameworks, the report also synthesizes current knowledge across a wide range of relevant domains. These include the etiology and epidemiology of fatty pancreas, as well as its associations with alcohol consumption, smoking, acute and chronic pancreatitis, pancreatic exocrine insufficiency, type 2 diabetes mellitus, and surgical outcomes. The potential links between fatty pancreas and neoplastic conditions such as intraductal papillary mucinous neoplasms and pancreatic cancer are also addressed, alongside the current understanding of its metabolic implications (beta‐cell function and glucose homeostasis) and treatment strategies. Throughout the consensus process, a consistent theme emerged: the limited availability of high‐quality, prospective clinical data. Therefore, many of the recommendations in this report are based on expert consensus rather than strong empirical evidence. As such, the statements require rigorous prospective validation before they can be adopted into routine clinical practice. This underscores a critical need for further research, particularly studies aimed at clarifying causal relationships, validating diagnostic tools, and determining the clinical relevance of fatty pancreas across diverse patient populations. This report serves as both a summary of our current understanding and a roadmap for future investigations, aiming to close existing knowledge gaps and guide evidence‐based clinical practice in this emerging field.
27 September 2021 in Acta gastroenterológica latinoamericana
The concept and diagnostic criteria for autoimmune pancreatitis have evolved since the first case reports published in the 1960s. The advances in knowledge during the past two decades have resulted in the recognition of several pancreatic conditions that show, on histological evaluation, variable combinations of inflammation and fibrosis. In fact, autoimmune pancreatitis comprises two distinct diseases: type 1 and type 2. Type 2 autoimmune pancreatitis is a particular pancreatic disease about which there is limited data; it differs from the ‘classic’ IgG4-related type 1 autoimmune pancreatitis in terms of epidemiology, pathological characteristics and natural evolution. There are patients with complex pancreatic conditions where an autoimmune component and good response to steroids are demonstrated, but they do not meet the suggested criteria for the diagnosis of type 1 or type 2 autoimmune pancreatitis. Although the term steroid-responsive pancreatitis may be interpreted as a synonym to type 1 and 2 autoimmune pancreatitis, these are not the only pancreatic conditions that improve with this type of treatment. Here, we present three clinical cases and a literature review related to the diagnosis and treatment of autoimmune pancreatitis and other less frequent pancreatic disorders that present a good response to steroid therapy.
28 August 2020 in Acta gastroenterológica latinoamericana
Club del Páncreas de la República Argentina Directores: Gustavo Kohan,34 Mariano Moro2 Coordinadores por Especialidad Gastroenterología: Dra. Analía Pasqua1 Diagnóstico por imágenes: Dr. Mariano Volpacchio31 Endoscopía: Dr. Federico Marcaccio18 Anatomía patológica: Dra. Mirta Kujaruk16 Oncología: Dra. Marcela Carballido7 Cirugía: Dr. Oscar María Mazza33 Nutrición: Lic. Marisa Canicoba5 Participantes Analía Pasqua,1 Mariano Moro,2 Lisandro Alle,3 Sandra …
30 June 2023 in Acta gastroenterológica latinoamericana
La pancreatitis crónica es una entidad dinámica y progresiva. Las interacciones entre los distintos factores de riesgo definen las manifestaciones clínicas y el perfil de complicaciones de cada paciente individual. La evaluación y el manejo del dolor y de las insuficiencias funcionales son los pilares del plan de cuidados de los pacientes con esta condición. La educación para la corrección de los factores de riesgo modificables es fundamental para impactar positivamente en la progresión de la enfermedad.
30 March 2022 in Acta gastroenterológica latinoamericana
El adenocarcinoma ductal de páncreas es considerado una de las neoplasias de peor pronóstico, ya que aproximadamente el 85% de los pacientes presenta una enfermedad avanzada en el momento del diagnóstico. Representa la cuarta causa de muerte por cáncer, y se estima que, en el año 2030, será la segunda causa. Esta situación exige que la comunidad médica esté capacitada para detectar y tratar integralmente a los pacientes con cáncer de páncreas, lo cual ha motivado el desarrollo de las recomendaciones consensuadas publicadas recientemente por el Club del Páncreas de la República Argentina.1
Pancreatic ductal adenocarcinoma (PDAC) remains clinically managed largely through anatomical stage and performance status, despite major inter-patient heterogeneity and dynamic pathway adaptation during progression. In this review, we propose a hypothesis-generating, stage-aware framework in which clinical stage and established molecular subtypes are considered complementary rather than competing stratification axes. Stage-resolved transcriptomic modeling identified a directional separation across up-front resectable, borderline/locally advanced, primary metastatic and liver metastatic samples, with PC1 explaining 51.1% of the variance and separating early from metastatic states, whereas PC2 explained 30.2% and captured immune/stromal remodeling. We interpret these observations cautiously as pathway-level signals that require functional and clinical validation, not as an established biological paradigm. The model suggests a transition from MAPK-enriched, proliferative and partially immune-competent tumors toward metastatic ecosystems characterized by PI3K-AKT-mTOR engagement, MYC amplification, mitochondrial metabolism, proteostasis support and immune exclusion. We further distinguish approved standards, negative clinical experiences, early clinical signals and preclinical hypotheses. The central conclusion is that PDAC therapeutic stratification should integrate stage, molecular subtype, treatment line, tissue context and evidence level before pathway-directed interventions are clinically prioritized. Accordingly, this review should be read as a translational prioritization framework rather than as a treatment algorithm: it organizes where pathway-directed hypotheses are most biologically plausible, where they are clinically supported, and where they remain insufficiently validated for routine decision-making.